Session

Opening Session Part I

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

UEG Research Prize 2022: Using integrated single cell genomics and spatial transcriptomics approaches to identify the key therapeutic targets driving the progression of human NASH
UEG Research Prize 2022: Using integrated single cell genomics and spatial transcriptomics approaches to identify the key therapeutic targets driving the progression of human NASH

Opening Session Part I

Target discovery for GI-diseases
Target discovery for GI-diseases

Opening Session Part I

Words of Welcome Opening Session Part I
Words of Welcome Opening Session Part I

Opening Session Part I

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Opening Session Part I  et al.

Item 1 - 5 / 5
1